AmyPore develops therapeutic solutions through our proprietary adaptive peptide platform, targeting the pathologies associated with intrinsically disordered proteins (IDPs) and membrane gangliosides.
The pioneering adaptive peptide concept developed by AmyPore opens new therapeutic avenues for diseases that currently have no effective treatment, by directly targeting the molecular mechanisms that cause them.
Our lead molecule, AmyP53, is the first adaptive peptide designed for the treatment of Alzheimer’s disease and Parkinson’s disease.
Our lead molecule, AmyP53, is a therapeutic peptide arising from fundamental research.
Its design rests on an innovative strategy built around a multiparametric set of requirements: targeting a molecular mechanism common to Alzheimer’s and Parkinson’s diseases, therapeutic action at low dose, absence of pre-clinical toxicity, and non-invasive administration (nasal spray).
AmyP53 is the first representative of a new therapeutic class for the treatment of Alzheimer’s and Parkinson’s diseases.
AmyP53 is active on neurons and astrocytes
AmyP53 is active on neurons and astrocytes
AmyPore is a Biotech founded in 2018 on the basis of the scientific discoveries of Pr. Nouara Yahi and Jacques Fantini, researchers in molecular neuroscience at the University of Aix-Marseille.
AmyPore is supported by the European Commission, Kedge Business School and the inter-university incubator IMPULSE.
The company obtained a grant H2020 SME Phase 1.
